Neutralization of the biological activity of cytokines and other protein effectors by antibody: Theoretical formulation of antibody titration curves in relation to antibody affinity

Journal of Immunological Methods

Volumn 278, Issue 1-2, 2003, Pages 127-144

  Kawade, Yoshimi ^a   Finter, Norman ^b   Grossberg, Sidney E ^c  

^a KYOTO UNIVERSITY   (Japan)

^b The Pyghtle   (United Kingdom)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Cytokines; Effector; Neutralization curve

Indexed keywords

ANTIGEN; CYTOKINE; NEUTRALIZING ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY TITER; ARTICLE; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TECHNIQUE; THEORETICAL MODEL;

EID: 0142071149     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(03)00203-5     Document Type: Article

References (25)

1. Antonelli G. In vivo development of antibody to interferons: an update to 1996. J. Interferon Cytokine Res. 17(Suppl. 1):1997;S39-S46.
2. Antonelli G., Dianzani F. Development of antibodies to interferon-beta in patients: technical and biological aspects. Eur. Cytokine Netw. 10:1999;413-442.
3. Antonelli G., Currenti M., Turriziani O., Dianzani F. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J. Infect. Dis. 163:1991;882-885.
4. Berg K., Billiau A., DeMaeyer E., Finter N.B., Galasso G., Grossberg S.E., Hilfenhaus J., Kawade Y., Meager A., Perkins F.T., Vilcek J., Trown P. WHO Tech. Rep. Ser. 687:1983;35-60.
5. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J., Martin-Dupont P., Michaud P., Papo T., Ugo V., Teyssandier I., Varet B., Mayeus P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346:2002;469-475.
6. Cummins J.M., Beilharz M.W., Krakowka S. Oral use of interferon. J. Interferon Cytokine Res. 19:1999;853-857.
7. Giovannoni G., Munschauer F.E. III, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 73:2002;465-469.
8. Grossberg S.E. Human antibody development to therapeutic biological response. Prog. Oncol. 13:1990;17-23.
9. Grossberg S.E., Kawade Y. The expression of potency of neutralizing antibodies for interferons and other cytokines. Biotheraphy. 10:1997;93-98.
10. Grossberg S.E., Kawade Y., Kohase M., Yokoyama H., Finter N. The neutralization of interferons by antibody: I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J. Interferon Cytokine Res. 21:2001;729-742.
11. Grossberg S.E., Kawade Y., Kohase M., Klein J.P. The neutralization of interferons by antibody: II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J. Interferon Cytokine Res. 21:2001;743-755.
12. Harlow E., Lane D. Antibody-antigen interaction. Using Antibodies: A Laboratory Manual. 1999;24-37 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
13. Hochuli E. Interferon immunogenicity: technical evaluation of interferon-alpha 2a. J. Interferon Cytokine Res. 17(Supplement 1):1997;S15-S21.
14. Kawade Y. An analysis of neutralization reaction of interferon by antibody: a proposal on the expression of neutralization titer. J. Interf. Res. 1:1980;61-70.
15. Kawade Y. Neutralization of activity of effector protein by monoclonal antibody: formulation of antibody dose-dependence of neutralization for an equilibrium system of antibody, effector, and its cellular receptor. Immunology. 56:1985;497-504.
16. Kawade Y. Quantitation of neutralization of interferon by antibody. Methods Enzymol. 119:1986;558-573.
17. Kawade Y., Watanabe Y. Neutralization of interferon by antibody: appraisals of methods of determining and expressing the neutralization titer. J. Interf. Res. 4:1984;571-584.
18. Kawade Y., Watanabe Y. The nature of neutralization reaction between effector protein and monoclonal antibody: a quantitative study of neutralization characteristics of anti-interferon antibodies. Immunology. 56:1985;489-495.
19. Lusher J.M. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials. Haematologica. 85:2000;2-5.
20. Meager A. Antibodies against interferons: characterisation of interferons and immunoassays. Clements M.J., Morris A.G., Gearing A.J.H. Lymphokines and Interferons: A Practical Approach. 1987;129 IRL Press, Oxford.
21. Meager A.M. Biological assays for interferons. J. Immunol. Methods. 261:2002;21-36.
22. Moore W.V., Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J. Clin. Endocrinol. Metab. 51:1980;691-697.
23. Ross C., Hansen M.B., Schyberg T., Berg K. Autoantibodies to crude human leukocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors. Clin. Exp. Immunol. 82:1990;57-62.
24. Ross C., Svenson M., Hansen M.B., Vejlsgaard G.L., Bendtzen K. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J. Clin. Invest. 95:1995;1974-1978.
25. Wadhwa M., Bird C., Dilger P., Mire-Sluis T., Thorpe R. Quantitative biological assays for individual cytokines. Balkwill F. Cytokine Cell Biology (Practical Approach Services). 2000;207 Oxford Univ. Press, Oxford.